Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population?

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 5, 2012, Pages 555-561

  Mandal, Raju Kumar ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Polymorphism; Prostate cancer

Indexed keywords

CELL DNA; CYCLIN D1; FAS ANTIGEN; PROTEIN MDM2;

ADULT; ALLELE; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; INDIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AGED; ALLELES; ANTIGENS, CD95; CASE-CONTROL STUDIES; CYCLIN D1; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS;

EID: 84866745036     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.05.006     Document Type: Article

References (32)

1. Hsing A.W., Tsao L., Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000, 85:60-67.
2. Sinha R., Anderson D.E., McDonald S.S., et al. Cancer risk and diet in India. J Postgrad Med 2003, 49:222-228.
3. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
4. Wagner U., Suess K., Luginbuhl T., et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999, 188:44-50.
5. Wang L.E., Cheng L., Spitz M.R., et al. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003, 42:1-8.
6. Haupt Y., Maya R., Kazaz A., et al. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
7. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
8. Leite K.R., Franco M.F., Srougi M., et al. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol 2001, 14:428-436.
9. Sherr C.J. Cancer cell cycles. Science (New York) 1996, 274:1672-1677.
10. Kibel A.S., Isaacs W.B. G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology 2000, 55:316-322.
11. Betticher D.C., Thatcher N., Altermatt H.J., et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995, 11:1005-1011.
12. Driver K.E., Song H., Lesueur F., et al. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis 2008, 29:333-341.
13. Wang L., Habuchi T., Mitsumori K., et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003, 103:116-120.
14. Liu B., Zhang Y., Jin M., et al. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog 2010, 49:75-84.
15. Huang Q.R., Morris D., Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997, 34:577-582.
16. Kanemitsu S., Ihara K., Saifddin A., et al. A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic Lupus erythematosus. J Rheumatol 2002, 29:1183-1188.
17. Sibley K., Rollinson S., Allan J.M., et al. Functional Fas promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003, 63:4327-4330.
18. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58.
19. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
20. Lum S.S., Chua H.W., Li H., et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 2008, 29:754-761.
21. Sanyal S., Festa F., Sakano S., et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004, 25:729-734.
22. Li C., Wu W., Liu J., et al. Functional polymorphisms in the promoter regions of the Fas and Fas ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 2006, 16:245-251.
23. Hu Z., Jin G., Wang L., et al. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 2007, 16:2717-2723.
24. Leite K.R., Franco M.F., Srougi M., et al. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol 2001, 14:428-436.
25. Stoehr R., Hitzenbichler F., Kneitz B., et al. Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Br J Cancer 2008, 99:78-82.
26. Singh V., Rastogi N., Mathur N., et al. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. AEP 2008, 18:48-57.
27. Kang S., Wang D.J., Li W.S., et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer 2009, 19:572-577.
28. Hong Y., Miao X., Zhang X., et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Can Res 2005, 65:9582-9587.
29. Wang L., Habuchi T., Mitsumori K., et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003, 103:116-120.
30. Rogers S., Wells R., Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986, 234:364-368.
31. Betticher D.C., Thatcher N., Altermatt H.J., et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995, 11:1005-1011.
32. Wang M., Wu D., Tan M., et al. Fas and Fas ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 2009, 47:559-568.